1. Home
  2. Analysis
  3. Stock
Stock

SELLAS Life Sciences Prices $150M Offering at $13 After 156% Phase 3 Rally

SELLAS Life Sciences priced a $150M stock offering at $13.00, a 27.6% discount to Wednesday's close, sending shares tumbling 20% premarket on dilution fears.

BMInsider desk · · 3 min read
A close-up, low-angle shot inside a sterile pharmaceutical cleanroom, where amber glass vials of leukemia immunotherapy vaccines move along a stainless steel automated conveyor belt under cool blue lighting. Gloved hands in white protective cleanroom suits inspect the sealed vials against an illuminated quality-control backdrop, with automated packaging machinery softly blurred in the background.

SELLAS Life Sciences Group priced a $150 million underwritten follow-on offering at $13.00 per share overnight, triggering a sharp premarket decline of roughly 20% on Thursday, November 19, 2026. The capital raise forces investors to weigh immediate equity dilution against the clinical breakthrough of its leukemia candidate following a 156% rally earlier this week.

What happened

Overnight into Thursday, SELLAS Life Sciences (Nasdaq: SLS) announced the pricing of 11,538,462 common shares at $13.00 each, aiming to raise $150.0 million in gross proceeds. The deal price marks a steep 27.6% discount to Wednesday’s closing price of $17.95. Joint book-running managers J.P. Morgan and TD Cowen received a 30-day option to buy up to an additional 1,730,769 shares, which could add $22.5 million.

The pricing abruptly halted momentum after SELLAS shares surged 156% following positive topline results from its pivotal Phase 3 REGAL trial for galinpepimut-S (GPS) in acute myeloid leukemia (AML). Ahead of Thursday's market open, SLS dropped about 20% to trade near $14.45.

Why it matters

Biotech companies rarely pass up the opportunity to tap capital markets after major clinical triumphs, and SELLAS followed that classic playbook. While the trial proved clinically potent—demonstrating a 41% reduction in the risk of death and extending median survival to 24.0 months—bringing a novel cancer therapy through regulatory approval requires substantial capital.

For retail shareholders who bought near Wednesday’s highs, the steep discount to institutional buyers hurts. Yet from a fundamental perspective, reading the balance sheet reveals why management acted decisively. Adding $150 million to the $134.7 million in cash SELLAS reported at the end of September removes going-concern risk and finances Biologics License Application (BLA) preparations. Management secured funding on strong terms relative to where the stock traded prior to the trial readout, even if short-term sentiment suffered.

What to watch next

  • Offering closing: The transaction is scheduled to close on Friday, November 20, 2026, subject to customary conditions.
  • Greenshoe execution: Whether underwriters exercise their option for 1.73 million additional shares within 30 days.
  • FDA timeline: Pre-BLA meeting scheduling and regulatory guidance for GPS in AML maintenance therapy.
  • Commercialization strategy: Potential regional partnerships or direct sales force investments in early 2027.
Sources (3)
  1. SELLAS Life Sciences Prices $150.0 Million Public Offering
  2. SELLAS Announces Positive Topline Phase 3 REGAL Trial Results
  3. SEC Form 10-Q (Q3 2026) - SELLAS Life Sciences Group

This analysis is for information only and is not investment advice. Prices and figures as of publication.

AI stock analysis

Any stock analysed in minutes

Business model, balance sheet, valuation and scenarios: aktienanalyse.ai builds a thorough analysis of any stock in minutes, with a fair value and bull, base and bear cases.

Analyse a stock → Stock profiles